• Loading stock data...
Does The Current Dip In Pfizer Stock Offer A Buying Opportunity? - WebTradeTalk Community
Thursday, May 19, 2022
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Login
WebTradeTalk Community
DigitalOcean Referral Badge
  • Home
  • Finance
    Why You (and I) Should Name a ‘Trusted Contact’

    Why You (and I) Should Name a ‘Trusted Contact’

    5 Things to Know About Truist Credit Cards

    5 Things to Know About Truist Credit Cards

    How to Sell Your Car Online

    How to Sell Your Car Online

    How to Book the Star Wars Hotel With Points

    How to Book the Star Wars Hotel With Points

    Lightspeed Restaurant Review 2021: Pricing, Features, Alternatives

    Charles Schwab vs. Robinhood: 2022 Comparison

    Is an Airbnb or a Hotel Right for Your Next Trip?

    Is an Airbnb or a Hotel Right for Your Next Trip?

    How to Insure Your Money When You’re Banking Over $250K

    How to Insure Your Money When You’re Banking Over $250K

    How Does AutoSlash Work? – webtradetalk.com

    How Does AutoSlash Work? – webtradetalk.com

    Smart Money Podcast: COVID Tests, and Reversing a Credit Score Drop

    Smart Money Podcast: The Tax Episode

  • Investing
    Best Stocks Under $5 That Pay Dividends

    Best Stocks Under $5 That Pay Dividends

    10 Best Oil Stocks to Buy Now

    10 Best Oil Stocks to Buy Now

    Best Platforms to Invest in Art

    Best Platforms to Invest in Art

    Hot Cash Stocks for 2022

    Hot Cash Stocks for 2022

    What is the DAX Stock Index?

    What is the DAX Stock Index?

    10 Smart Things To Do With Your Tax Refund

    10 Smart Things To Do With Your Tax Refund

    How to Spot a Crypto Scam (In-Depth Guide)

    How to Spot a Crypto Scam (In-Depth Guide)

    Why You Should Probably Keep Your Distance

    Why You Should Probably Keep Your Distance

    5 Factors To Look For When Investing In An NFT Project

    5 Factors To Look For When Investing In An NFT Project

  • Stock
  • Forex Trading
    Sterling slips in Brexit countdown, Aussie rallies By Reuters

    Forex – Dollar Slides After 4-month High; Aussie Firmer On RBA’s Optimism By Investing.com

    Argentina Peso Tumbles on Bid to Tap $50 Billion IMF Line Faster By Bloomberg

    Argentina Tested as Peso Selloff Prompts Third Abrupt Increase By Bloomberg

    Dollar Drifts Lower as Treasury Yields Retreat By Investing.com

    Dollar Hits Fresh 4-Month High After Mixed Jobs Report By Investing.com

    Dollar Flat After Fed; Aussie Dollar Falls on Weak China PPI Data By Investing.com

    Dollar Eases From 2018 Highs as Wage Growth Woes ‘Puzzle’ Traders By Investing.com

    Virus worries buoy dollar, pound swung by Brexit gyrations By Reuters

    Forex – Weekly Outlook: May 7

    Brexit sterling bets pose no conflict for UK’s Johnson: government By Reuters

    Dollar index at near four-month high after U.S. jobs data By Reuters

    Taiwan probes foreign banks over grain firms’ arbitrage By Reuters

    Forex – Dollar Steady at 4-month High; Aussie Up On Business Confidence By Investing.com

    Dollar Rises as Markets Temper Hopes on Trade, Brexit By Investing.com

    Dollar Holds Near 4-Month High in 4th Week of Gains By Investing.com

    EUR/USD Weakness Limits Dollar’s Retreat From Highs By Investing.com

    EUR/USD Weakness Limits Dollar’s Retreat From Highs By Investing.com

  • Crypto
    Terra (LUNA) Outperforms Popular Cryptos Ether, Dogecoin In The Past 24 Hours

    Terra (LUNA) Outperforms Popular Cryptos Ether, Dogecoin In The Past 24 Hours

    Proof-of-Work Ban Removed From Europe’s Proposed Crypto Regulation – Regulation Bitcoin News

    Proof-of-Work Ban Removed From Europe’s Proposed Crypto Regulation – Regulation Bitcoin News

    GameFi – Play Hard, Earn Hard

    GameFi – Play Hard, Earn Hard

    Square Enix to Bring Dungeon Siege IP to The Sandbox – Metaverse Bitcoin News

    Square Enix to Bring Dungeon Siege IP to The Sandbox – Metaverse Bitcoin News

    Crypto Market Rebounds As Tech firms Boycott Russia

    Crypto Market Rebounds As Tech firms Boycott Russia

    South African Crypto Exchange Valr Raises $50 Million in Series B Funding Round – Exchanges Bitcoin News

    South African Crypto Exchange Valr Raises $50 Million in Series B Funding Round – Exchanges Bitcoin News

    How 4DOT is making DeFi Accessible to Crypto Investors

    How 4DOT is making DeFi Accessible to Crypto Investors

    Technical Analysis:  Fantom Climbs Close to 10% Higher, While THETA Drops on Wednesday – Market Updates Bitcoin News

    Technical Analysis:  Fantom Climbs Close to 10% Higher, While THETA Drops on Wednesday – Market Updates Bitcoin News

    US Senator Urges Regulators to Increase Scrutiny on Crypto as It Risks Undermining Sanctions Against Russia – Bitcoin News

    US Senator Urges Regulators to Increase Scrutiny on Crypto as It Risks Undermining Sanctions Against Russia – Bitcoin News

  • Donate
No Result
View All Result
  • Home
  • Finance
    Why You (and I) Should Name a ‘Trusted Contact’

    Why You (and I) Should Name a ‘Trusted Contact’

    5 Things to Know About Truist Credit Cards

    5 Things to Know About Truist Credit Cards

    How to Sell Your Car Online

    How to Sell Your Car Online

    How to Book the Star Wars Hotel With Points

    How to Book the Star Wars Hotel With Points

    Lightspeed Restaurant Review 2021: Pricing, Features, Alternatives

    Charles Schwab vs. Robinhood: 2022 Comparison

    Is an Airbnb or a Hotel Right for Your Next Trip?

    Is an Airbnb or a Hotel Right for Your Next Trip?

    How to Insure Your Money When You’re Banking Over $250K

    How to Insure Your Money When You’re Banking Over $250K

    How Does AutoSlash Work? – webtradetalk.com

    How Does AutoSlash Work? – webtradetalk.com

    Smart Money Podcast: COVID Tests, and Reversing a Credit Score Drop

    Smart Money Podcast: The Tax Episode

  • Investing
    Best Stocks Under $5 That Pay Dividends

    Best Stocks Under $5 That Pay Dividends

    10 Best Oil Stocks to Buy Now

    10 Best Oil Stocks to Buy Now

    Best Platforms to Invest in Art

    Best Platforms to Invest in Art

    Hot Cash Stocks for 2022

    Hot Cash Stocks for 2022

    What is the DAX Stock Index?

    What is the DAX Stock Index?

    10 Smart Things To Do With Your Tax Refund

    10 Smart Things To Do With Your Tax Refund

    How to Spot a Crypto Scam (In-Depth Guide)

    How to Spot a Crypto Scam (In-Depth Guide)

    Why You Should Probably Keep Your Distance

    Why You Should Probably Keep Your Distance

    5 Factors To Look For When Investing In An NFT Project

    5 Factors To Look For When Investing In An NFT Project

  • Stock
  • Forex Trading
    Sterling slips in Brexit countdown, Aussie rallies By Reuters

    Forex – Dollar Slides After 4-month High; Aussie Firmer On RBA’s Optimism By Investing.com

    Argentina Peso Tumbles on Bid to Tap $50 Billion IMF Line Faster By Bloomberg

    Argentina Tested as Peso Selloff Prompts Third Abrupt Increase By Bloomberg

    Dollar Drifts Lower as Treasury Yields Retreat By Investing.com

    Dollar Hits Fresh 4-Month High After Mixed Jobs Report By Investing.com

    Dollar Flat After Fed; Aussie Dollar Falls on Weak China PPI Data By Investing.com

    Dollar Eases From 2018 Highs as Wage Growth Woes ‘Puzzle’ Traders By Investing.com

    Virus worries buoy dollar, pound swung by Brexit gyrations By Reuters

    Forex – Weekly Outlook: May 7

    Brexit sterling bets pose no conflict for UK’s Johnson: government By Reuters

    Dollar index at near four-month high after U.S. jobs data By Reuters

    Taiwan probes foreign banks over grain firms’ arbitrage By Reuters

    Forex – Dollar Steady at 4-month High; Aussie Up On Business Confidence By Investing.com

    Dollar Rises as Markets Temper Hopes on Trade, Brexit By Investing.com

    Dollar Holds Near 4-Month High in 4th Week of Gains By Investing.com

    EUR/USD Weakness Limits Dollar’s Retreat From Highs By Investing.com

    EUR/USD Weakness Limits Dollar’s Retreat From Highs By Investing.com

  • Crypto
    Terra (LUNA) Outperforms Popular Cryptos Ether, Dogecoin In The Past 24 Hours

    Terra (LUNA) Outperforms Popular Cryptos Ether, Dogecoin In The Past 24 Hours

    Proof-of-Work Ban Removed From Europe’s Proposed Crypto Regulation – Regulation Bitcoin News

    Proof-of-Work Ban Removed From Europe’s Proposed Crypto Regulation – Regulation Bitcoin News

    GameFi – Play Hard, Earn Hard

    GameFi – Play Hard, Earn Hard

    Square Enix to Bring Dungeon Siege IP to The Sandbox – Metaverse Bitcoin News

    Square Enix to Bring Dungeon Siege IP to The Sandbox – Metaverse Bitcoin News

    Crypto Market Rebounds As Tech firms Boycott Russia

    Crypto Market Rebounds As Tech firms Boycott Russia

    South African Crypto Exchange Valr Raises $50 Million in Series B Funding Round – Exchanges Bitcoin News

    South African Crypto Exchange Valr Raises $50 Million in Series B Funding Round – Exchanges Bitcoin News

    How 4DOT is making DeFi Accessible to Crypto Investors

    How 4DOT is making DeFi Accessible to Crypto Investors

    Technical Analysis:  Fantom Climbs Close to 10% Higher, While THETA Drops on Wednesday – Market Updates Bitcoin News

    Technical Analysis:  Fantom Climbs Close to 10% Higher, While THETA Drops on Wednesday – Market Updates Bitcoin News

    US Senator Urges Regulators to Increase Scrutiny on Crypto as It Risks Undermining Sanctions Against Russia – Bitcoin News

    US Senator Urges Regulators to Increase Scrutiny on Crypto as It Risks Undermining Sanctions Against Russia – Bitcoin News

  • Donate
No Result
View All Result
WebTradeTalk Community
No Result
View All Result
Home Stock

Does The Current Dip In Pfizer Stock Offer A Buying Opportunity?

Newsroom by Newsroom
February 12, 2022
in Stock
0
Does The Current Dip In Pfizer Stock Offer A Buying Opportunity?
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

The logo of US multinational pharmaceutical company Pfizer, is pictured at a factory in Puurs, where … [+] Covid-19 vaccines are being produced for Britain, on December 3, 2020. – Britain on December 2, 2020 became the first western country to approve a Covid-19 vaccine for general use, while Japan and Italy pledged free inoculations for all even as the global death toll rose towards 1.5 million. (Photo by Kenzo TRIBOUILLARD / AFP) (Photo by KENZO TRIBOUILLARD/AFP via Getty Images)


AFP via Getty Images

[Updated: Feb 11, 2022] Pfizer Q4 Earnings Update

The stock price of Pfizer (NYSE: PFE) has seen a fall of 8% over the last month, while it is down over 3% in a week. The recent decline can be attributed to the company’s mixed Q4 results, with sales falling below, and earnings above, the street estimates. Pfizer’s revenue of $23.8 billion in Q4 was up 106% y-o-y, but it fell short of the $24.2 consensus estimate. The sales growth was largely driven by its Covid-19 vaccine, which garnered $12.5 billion, taking the full-year 2021 vaccine sales north of $36 billion. Excluding the vaccine and the new Covid-19 treatment, Pfizer’s Q4 revenues actually declined by 2%. Looking at the bottom line, the company reported an adjusted EPS of $1.08, up 156% y-o-y, well above the $0.87 consensus estimate.

Looking forward, Pfizer expects 2022 revenue of $100 billion and EPS of $6.45 at the mid-point of the provided range. Note that out of $100 billion, $54 billion is expected from sales of the Covid-19 vaccine and treatment. Despite a strong earnings beat and strong outlook, PFE stock saw lower levels this week, as the investors were anticipating even higher sales in 2022. It should be noted that Pfizer’s projections of Covid-19 vaccine and treatment sales are based on deals already made, and the figure is likely to inch higher as the year progresses.

We have also updated our model for Pfizer to reflect the latest earnings. We now expect the total sales to top $105 billion, and adjusted EPS to be $6.90, well above the company’s provided guidance. We now estimate Pfizer’s Valuation to be $63 per share, which is 23% above the current market price of $51, implying that the current dip in PFE stock is a good buying opportunity for higher gains in the long term. This represents a P/E ratio of 9x based on our forecast of $6.90 EPS in 2022. The 9x figure compares with an average of around 11x seen between 2019 and 2021.

But what about the near-term outlook for PFE stock?

Given that PFE stock has seen a decline of 8% in a month, will it continue its downward trajectory, or is a rise imminent? Going by historical performance, there is a good chance of a rise in PFE stock over the next month. Out of 106 instances in the last ten years that PFE stock saw a twenty-one-day fall of 8% or more, 68 of them resulted in PFE stock rising over the subsequent one-month period (twenty-one trading days). This historical pattern reflects 68 out of 106, or a good 64% chance of a rise in PFE stock over the coming month, implying that PFE stock is a good bet at its current levels, even for the short term, in our view. See our analysis on Pfizer Stock Chance of A Rise for more details.

Below you’ll find our previous coverage of PFE stock where you can track our view over time.

[Updated: Dec 16, 2021] Pfizer Stock Rise

The stock price of Pfizer (NYSE: PFE) has outperformed the broader indices. While the S&P500 index has seen a rise of 1% over the last month or so, PFE stock is up a solid 19%. This also compares with -10% returns for its peer – Merck, and 5% growth for Johnson & Johnson. PFE stock is also up over 14% over the last week, and it was up 6% yesterday after it reported that its antiviral pill reduces the risk of hospitalization and death from Covid-19 by nearly 90%. This is far more effective than a similar pill from Merck, partly explaining the decline in MRK stock.

Looking forward, the company is likely to continue to benefit from its vaccine now that several countries have approved the booster shots, and the new pill will also result in an uptick in overall sales, subject to regulatory approval. That said, going by our Pfizer’s Valuation, with an EPS estimate of $4.42 and a P/E multiple of around 13x in 2021, this translates into a price of $58, which is slightly below the current market price of around $59, implying that PFE stock is now fully valued, and it may be prudent for investors to wait for a dip to buy it.

But what about the near term, given that PFE stock has seen a sharp rise of 18% in a month? Going by its historical performance, there is a higher chance of a fall in PFE stock over the next month. Out of 23 instances in the last ten years that PFE stock saw a twenty-one day rise of 18% or more, only 10 of them resulted in PFE stock rising over the subsequent one-month period (twenty-one trading days). This historical pattern reflects 10 out of 23, or only a 43% chance of a rise in PFE stock over the coming month. See our analysis on Pfizer Stock Chances of Rise for more details.

While PFE stock may see lower levels going forward, it is helpful to see how its peers stack up. Check out Pfizer Stock Comparison With Peers to see how PFE stock compares against peers on metrics that matter. You can find more such useful comparisons on Peer Comparisons.

Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last ten years data

  • After moving 14.4% or more over a five-day period, the stock rose in the next five days on 50% of the occasions.
  • After moving 7.5% or more over a ten-day period, the stock rose in the next ten days on 64% of the occasions
  • After moving 18.4% or more over a twenty-one-day period, the stock rose in the next twenty-one days on 43% of the occasions.

This pattern suggests that there are higher chances of a rise in PFE stock over the next ten days, but it is likely to see lower levels over the next month or so, implying that PFE stock is currently best avoided in the near term.

Pfizer Stock Return (Recent) Comparison With Peers

  • Five-Day Return: PFE highest at 14.4%; RHHBY lowest at -2.6%
  • Ten-Day Return: LLY highest at 10.5%; RHHBY lowest at 0.5%
  • Twenty-One Days Return: PFE highest at 18.4%; MRK lowest at -10.0%

[Updated: Nov 18, 2021] Pfizer Stock Update

The stock price of Pfizer (NYSE: PFE) has seen a rise of 21% in a month following multiple positive developments, including positive data for its oral Covid-19 treatment pill, upbeat Q3 results, and more recently, closing the acquisition of Trillium Therapeutics for $2.3 billion. Pfizer announced its plans to acquire Trillium in August this year, while it made an initial investment of $25 million last year. Trillium’s pipeline, which includes TT-621 and TT-622, appears to be a good fit for Pfizer. TT-621 is a novel checkpoint inhibitor that activates anti-tumor activity by blocking the CD47 signal, while TT-622 is a fusion protein being tested for the treatment of lymphoma, multiple myeloma, and solid tumors.

But now that PFE stock has seen a 21% rise in a month, outperforming its peers with MRK stock up 7% and JNJ stock up just 2%, will it continue its upward trajectory, or is a fall imminent? Going by historical performance, there is still a higher chance of a rise in PFE stock over the next month. Note that such a large move (over 20%) in a month is very rare for Pfizer and it has occurred only 12 times in the last ten years. Out of 12 such instances, 7 of them resulted in PFE stock rising over the subsequent one-month period (twenty-one trading days). This historical pattern reflects 7 out of 12, or about a 58% chance of a rise in PFE stock over the coming month. See our analysis on Pfizer Stock Chances of Rise for more details.

Even if we were to look at our Pfizer’s Valuation, with an EPS estimate of around $4.40 and a P/E multiple of around 13x in 2021, this translates into a price of $56, which is 10% above the current market price of around $50, implying that there is still some room for growth in PFE stock. The company’s leading position in Covid-19 vaccines as well as its effective treatment for Covid-19 (pending for regulatory approval) are some of the near term triggers that will likely bolster its stock price growth.

While PFE stock may see higher levels going forward, it is helpful to see how its peers stack up. Check out Pfizer Stock Comparison With Peers to see how PFE stock compares against peers on metrics that matter. You can find more such useful comparisons on Peer Comparisons.

Pfizer Stock Return (Recent) Comparison With Peers

  • Five-Day Return: PFE highest at 3.8%; MRK lowest at -1.7%
  • Ten-Day Return: PFE highest at 13.5%; MRK lowest at -6.9%
  • Twenty-One Days Return: PFE highest at 20.9%; JNJ lowest at -0.4%

 

[Updated: Nov 8, 2021] PFE Stock Rise

The stock price of Pfizer (NYSE: PFE) surged 11% in a single day on Friday Nov 5, 2021. The rise can be attributed to the company announcing positive data for its oral pill for the treatment of Covid-19. Pfizer’s Covid-19 pill used in combination with an HIV drug cuts the risk of hospitalization or death by 89% in high-risk adults who’ve been exposed to the Covid-19 virus. [1] Pfizer’s oral pill is now the second antiviral pill after Merck’s to demonstrate strong effectiveness for treating Covid-19. The company will now seek regulatory approvals for this pill. Note that Pfizer’s pill appears to be more effective over Merck’s, which reduces the risk of hospitalization and death by 50% for patients with mild to moderate Covid-19.

Last week, Pfizer also released its upbeat Q3 results, with revenue of $24.1 billion, compared to our forecast of $23.5 billion and $22.6 billion consensus estimate. The company’s bottom-line of $1.34 on a per share and adjusted basis was up a solid 133% y-o-y, and compares with our forecast of $1.35 and consensus estimate of $1.08. The Covid-19 vaccine continued to be the key growth driver with sales of $13 billion during the quarter. The nine month sales (ending Sep 2021) for the vaccine now stands at over $24 billion, and Pfizer now forecasts its sales to be around $36 billion for the full-year 2021, and another $29 billion in 2022. Our dashboard on Pfizer Revenues offers more details on the company’s segments.

While the vaccine sales figures are in-line with our earlier forecasts, the oral pill is something that investors will be looking forward to. The Covid-19 vaccine sales are expected to decline with rising global vaccination rates, but the Covid-19 oral pills could garner recurring revenues for Pfizer in the years to come. The U.S. government has been in negotiations with Pfizer for 1.7 million courses of treatment, with an additional option for 3.3 million at a price of $700 per treatment, implying a potential revenue of as high as $3.5 billion from the U.S. government alone. [2]

Taking into account the company’s Q3 results as well as the positive data from its oral pill for Covid-19, we have now revised our Pfizer’s Valuation to $56 per share based on adjusted EPS of $4.40 and 12.7x P/E multiple in 2021. This reflects a premium of 8% to our prior estimate of $52. The change stems primarily from an upward revision in P/E multiple, as the earnings growth for Pfizer over the coming years is now expected to be better than our earlier estimates, given the potential recurring revenues from its oral pill (subject to regulatory approval) as well as some contribution from its Covid-19 vaccine, while its non-Covid-19 related business sees steady growth. Overall, we believe that despite a large 11% rise for PFE stock in a day, it has more room for growth, and it is likely to see higher levels going forward.

[Updated: Nov 1, 2021] PFE Q3 Earnings Preview

Pfizer (NYSE: PFE) is scheduled to report its Q3 2021 results on Tuesday, November 2. We expect the company to likely post revenue and earnings well above the consensus estimates, primarily led by its Covid-19 vaccine. Pfizer should see an overall pickup in pharmaceutical demand due to an increase in hospital visits with economies opening up gradually. We expect the company to navigate well based on these trends over the latest quarter. Furthermore, we also think PFE stock remains attractive at the current valuation. Trefis’ forecast indicates that Pfizer’s valuation is $52 per share, which is 18% above the current market price of $44. Our interactive dashboard analysis on Pfizer’s Pre-Earnings has additional details.

(1) Revenues expected to be above the consensus estimates

Trefis estimates Pfizer’s Q3 2021 revenues to be around $23.5 billion, 4% above the $22.6 billion consensus estimate. Now that the economies are opening up with vaccination programs underway in multiple countries, pharmaceutical companies will likely benefit from an increase in the volume of new patient starts. For Pfizer, its Covid-19 vaccine remains the key growth driver in the near term, with 2021 annual sales projected to be as high as $35 billion, per Trefis estimates.

Pfizer’s Q2 2021 sales were up 86% y-o-y to $19.0 billion, primarily driven by $7.8 billion sales from its Covid-19 vaccine, and the contribution of this vaccine is expected to remain high in Q3. Overall, it appears that the Covid-19 vaccine will continue to drive the company’s top and bottom line expansion for now, but leaving that aside, revenue for its other drugs grew 10% in Q2, led by strong growth in biosimilars and alliance revenues, a trend expected to continue in the near term. Our dashboard on Pfizer Revenues offers more details on the company’s segments.

2) EPS likely to be above the consensus estimates

Pfizer’s Q3 2021 adjusted earnings per share is expected to be $1.35 per Trefis analysis, compared to the consensus estimate of $1.08. Pfizer’s adjusted net income of $6.1 billion in Q2 2021 reflected a large 75% rise from its $3.5 billion figure in the prior-year quarter, primarily due to higher revenues. For the full year 2021, we expect the adjusted EPS to be higher at $4.65 compared to $2.22 in 2020.

(3) Stock price estimate 18% above the current market price

Going by our Pfizer’s Valuation, with an EPS estimate of $4.65 and a P/E multiple of 11x in 2021, this translates into a price of $52, over 18% higher than the current market price of $44. While the 11x figure is lower than the levels of over 14x seen in 2018 and 16x as recently as late 2020, this can be attributed to the fact that Pfizer’s EPS will be very high in 2021, followed by a decline from 2022 onward, with a slowdown in Covid-19 vaccine sales. Look at our Covid-19 Vaccine Updates for more details.

Note: P/E Multiples are based on Share Price at the end of the year and reported (or expected) Adjusted Earnings for the full year.

While PFE stock is worth considering for more gains, it is helpful to see how its peers stack up. Check out how Pfizer Peers fare on metrics that matter. You will find other useful comparisons for companies across industries at Peer Comparisons.

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.

Return


Trefis

 Invest with Trefis Market Beating Portfolios

See all Trefis Price Estimates

Source link

Tags: BuyingCurrentDipOfferOpportunityPfizerStock
Previous Post

Bandai Namco to Invest $130 Million in Building Its Own IP Metaverse – Metaverse Bitcoin News

Next Post

Firmer U.S. dollar boosts corporate interest in currency hedging By Reuters

Newsroom

Newsroom

Related Posts

Is $100 Oil A Catalyst For Tesla Stock?
Stock

Is $100 Oil A Catalyst For Tesla Stock?

by Newsroom
March 3, 2022
Warburg Pincus-Backed ESR To Build $1.5 Billion Logistics Park In Osaka Amid E-Commerce Boom
Stock

Warburg Pincus-Backed ESR To Build $1.5 Billion Logistics Park In Osaka Amid E-Commerce Boom

by Newsroom
March 3, 2022
Singapore’s ST Telemedia Buys Stake In Philippines’ Globe Data Center Unit In Deal Valued At $350 Million
Stock

Singapore’s ST Telemedia Buys Stake In Philippines’ Globe Data Center Unit In Deal Valued At $350 Million

by Newsroom
March 3, 2022
“Black Digital Spaces Are A Vital Transformative Tool”
Stock

“Black Digital Spaces Are A Vital Transformative Tool”

by Newsroom
March 3, 2022
Home Builders Trade At Low Multiples. Are They A Value?
Stock

Home Builders Trade At Low Multiples. Are They A Value?

by Newsroom
March 3, 2022
Next Post
Virgin Islands Suspends Nearly $1 Billion Bond Sale By Bloomberg

Firmer U.S. dollar boosts corporate interest in currency hedging By Reuters

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent Articles

Sterling slips in Brexit countdown, Aussie rallies By Reuters

Forex – Dollar Slides After 4-month High; Aussie Firmer On RBA’s Optimism By Investing.com

March 3, 2022
Why You (and I) Should Name a ‘Trusted Contact’

Why You (and I) Should Name a ‘Trusted Contact’

March 3, 2022
Terra (LUNA) Outperforms Popular Cryptos Ether, Dogecoin In The Past 24 Hours

Terra (LUNA) Outperforms Popular Cryptos Ether, Dogecoin In The Past 24 Hours

March 3, 2022

Browse by Category

  • Crypto
  • Finance
  • Forex Trading
  • Investing
  • Stock

About us

Our mission is to develop a community of people who try to make financially sound decisions. The website strives to educate individuals in making wise choices about Personal Finance, Stock, Investing, Crypto, and more.

Categories

  • Crypto
  • Finance
  • Forex Trading
  • Investing
  • Stock

Recent Posts

  • Forex – Dollar Slides After 4-month High; Aussie Firmer On RBA’s Optimism By Investing.com
  • Why You (and I) Should Name a ‘Trusted Contact’
  • Terra (LUNA) Outperforms Popular Cryptos Ether, Dogecoin In The Past 24 Hours
  • Contact
  • Privacy Policy
  • Terms & Conditions

© 2021 webtradetalk.com - All rights reserved

No Result
View All Result
  • Home
  • Finance
  • Investing
  • Stock
  • Forex Trading
  • Crypto
  • Donate

© 2021 webtradetalk.com - All rights reserved

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
  • bitcoinBitcoin(BTC)$60,736.00-1.05%
  • MMS Cash TokenMMS Cash Token(MCASH)$1.000.00%
  • ethereumEthereum(ETH)$4,240.29-1.27%
  • binancecoinBinance Coin(BNB)$516.85-0.75%
  • tetherTether(USDT)$1.00-0.09%
  • cardanoCardano(ADA)$1.96-0.75%
  • SolanaSolana(SOL)$196.662.08%
  • rippleXRP(XRP)$1.091.42%
  • polkadotPolkadot(DOT)$42.28-1.30%
  • Shiba InuShiba Inu(SHIB)$0.000067-5.05%
  • dogecoinDogecoin(DOGE)$0.261766-4.15%
  • usd-coinUSD Coin(USDC)$1.00-0.08%
  • TerraTerra(LUNA)$42.35-2.09%
  • AvalancheAvalanche(AVAX)$63.120.93%
  • wrapped-bitcoinWrapped Bitcoin(WBTC)$60,784.00-0.96%
  • chainlinkChainlink(LINK)$29.46-1.35%
  • Binance USDBinance USD(BUSD)$1.00-0.14%
  • litecoinLitecoin(LTC)$190.63-0.15%
  • UniswapUniswap(UNI)$24.680.07%
  • matic-networkPolygon(MATIC)$1.85-1.97%
  • algorandAlgorand(ALGO)$1.820.55%
  • bitcoin-cashBitcoin Cash(BCH)$593.931.51%
  • cosmosCosmos(ATOM)$36.33-3.38%
  • stellarStellar(XLM)$0.3666102.15%
  • vechainVeChain(VET)$0.130379-1.17%
  • Axie InfinityAxie Infinity(AXS)$137.08-5.29%
  • Internet ComputerInternet Computer(ICP)$45.074.39%
  • daiDai(DAI)$1.00-0.06%
  • filecoinFilecoin(FIL)$63.938.88%
  • tronTRON(TRX)$0.099972-0.89%
  • theta-tokenTheta Network(THETA)$7.12-7.47%
  • ethereum-classicEthereum Classic(ETC)$53.802.21%
  • FTX TokenFTX Token(FTT)$58.46-1.92%
  • FantomFantom(FTM)$2.68-1.66%
  • cETHcETH(CETH)$85.17-1.02%
  • VectoriumVectorium(VECT)$425.81-3.49%
  • HederaHedera(HBAR)$0.401606-3.25%
  • Lido Staked EtherLido Staked Ether(STETH)$4,218.57-0.97%
  • OKBOKB(OKB)$20.58-2.77%
  • tezosTezos(XTZ)$6.26-1.07%
  • ElrondElrond(EGLD)$264.881.10%
  • Crypto.com CoinCrypto.com Coin(CRO)$0.208427-3.29%
  • NearNear(NEAR)$9.86-6.89%
  • The GraphThe Graph(GRT)$0.995.37%
  • moneroMonero(XMR)$268.562.08%
  • eosEOS(EOS)$4.562.83%
  • FlowFlow(FLOW)$13.88-4.08%
  • PancakeSwapPancakeSwap(CAKE)$17.40-3.20%
  • AaveAave(AAVE)$310.80-2.66%
  • KlaytnKlaytn(KLAY)$1.58-1.86%